A Selective Separation Mechanism for Mono/divalent Cations and Properties of a Hollow-Fiber Composite Nanofiltration Membrane Having a Positively Charged Surface.

Positively charged nanofiltration (NF) technology is considered a green and low-cost method for mono/divalent cation separation. Nevertheless, the separation rejection mechanisms of these NF membranes have yet to be extensively investigated. In this work, we fabricated a thin-film composite (TFC) hollow-fiber (HF) NF membrane with a positively charged surface via modification of the nascent interfacial polymerization layer using a branched polyethyleneimine (BPEI)/ethanol solution. Then, we extensively investigated its selective separation mechanism for mono/divalent cations. We proposed and proved that there exists a double-charged layer near the membrane surface, which helps to repel the divalent cations selectively via Donnan exclusion while promoting the fast penetration of monovalent cations. Meanwhile, the membrane skin layer is loose and hydrophilic due to the loose BPEI structure and the abundance of amine groups, as well as the changed fabrication conditions. In this way, we achieved very good mono/divalent cation selectivity and relatively high water permeance for the as-prepared HF NF membrane. We also obtained good anti-fouling, anti-scaling, and acid resistance, and long-term stability as well, which are urgently needed during practical application. Furthermore, we successfully amplified this HF NF membrane and proved that it has broad application prospects in mono/divalent cation separation.

Hollow Fiber Membrane for Organic Solvent Nanofiltration: A Mini Review.

Organic solvents take up 80% of the total chemicals used in pharmaceutical and related industries, while their reuse rate is less than 50%. Traditional solvent treatment methods such as distillation and evaporation have many disadvantages such as high cost, environmental unfriendliness, and difficulty in recovering heat-sensitive, high-value molecules. Organic solvent nanofiltration (OSN) has been a prevalent research topic for the separation and purification of organic solvent systems since the beginning of this century with the benefits of no-phase change, high operational flexibility, low cost, as well as environmental friendliness. Especially, hollow fiber (HF) OSN membranes have gained a lot of attention due to their high packing density and easy scale-up as compared with flat-sheet OSN membranes. This paper critically reviewed the recent research progress in the preparation of HF OSN membranes with high performance, including different materials, preparation methods, and modification treatments. This paper also predicts the future direction of HF OSN membrane development.

LncRNA TUG1 promotes cells proliferation and inhibits cells apoptosis through regulating AURKA in epithelial ovarian cancer cells.

This study aimed to assess the effect of long noncoding RNAs (lncRNAs) taurine-upregulated gene 1 (TUG1) on cells proliferation and apoptosis as well as its targeting genes in epithelial ovarian cancer (EOC) cells.Blank mimic, lncRNA TUG1 mimic, blank inhibitor, and lncRNA TUG1 inhibitor plasmids were transfected into SK-OV-3 (SKOV3) cells. Rescue experiment was performed by the transfection of lncRNA TUG1 inhibitor and Aurora kinase A (AURKA) mimic plasmids into SKOV3 cells. Cell counting kit-8 (CKK-8), annexin V-FITC (AV)-propidium iodide (PI) (AV-PI), quantitative polymerase chain reaction (qPCR), and western blot assays were performed to detect cells proliferation, apoptosis, RNA expression, and protein expression respectively.Cells proliferation was increased in lncRNA TUG1 mimic group and decreased in lncRNA TUG1 inhibitor group than normal control (NC) groups. Cells apoptosis rate was repressed after treatment with lncRNA TUG1 mimic and promoted after treatment with lncRNA TUG1 inhibitor. AURKA expression but not CLDN3, SERPINE1, or ETS1 expression was adversely regulated by lncRNA TUG1 mimic and inhibitor. After transferring lncRNA TUG1 (-) and AURKA (+) plasmids, cells proliferation was increased, while cells apoptosis rate was decreased in AURKA mimic (+)/lncRNA TUG1 inhibitor (-) group than NC (+)/lncRNA TUG1 (-) group, which suggested lncRNA TUG1 regulated cells proliferation and cells apoptosis through targeting AURKA.LncRNA TUG1 promotes cells proliferation and inhibits cells apoptosis through regulating AURKA in EOC cells.

Long non-coding RNA taurine-upregulated gene 1 predicts unfavorable prognosis, promotes cells proliferation, and inhibits cells apoptosis in epithelial ovarian cancer.

The aim of this study was to evaluate the correlation of long non-coding RNAs (lncRNAs) taurine-upregulated gene 1 (TUG1) with clinicopathological characteristics as well as overall survival (OS) in epithelial ovarian cancer (EOC) patients, and investigate its function in EOC cells proliferation and apoptosis in vitro.LncRNA TUG1 expressions were detected in tumor tissues and paired adjacent tissues obtained from 96 EOC patients. Blank mimic, lncRNA TUG1 mimic, blank inhibitor, and lncRNA TUG1 inhibitor plasmids were transfected into SKOV3 cells. CKK-8, annexin V-FITC-propidium iodide, qPCR and western blot assays were performed to detect cells proliferation, cells apoptosis, RNA expression, and protein expression, respectively.LncRNA TUG1 expression was higher in tumor tissue compared to paired adjacent tissue (P < .001), and it was positively correlated with pathological grade (P = .022), tumor size (P = .011) and FIGO stage (P < .001). Kaplan-Meier curve showed that lncRNA TUG1 high expression was associated with worse OS (P = .003). Multivariate Cox analysis indicated that lncRNA TUG1 high expression (vs. low expression) (P = .035) was independently predictive factor for shorter OS. In vitro, cells proliferation was promoted after treatment with lncRNA TUG1 mimic and was suppressed after treatment with lncRNA TUG1 inhibitor. In addition, cells apoptosis rate was decreased in lncRNA TUG1 mimic group compared to NC1 mimic, and increased in lncRNA TUG1 inhibitor group compared to NC2 inhibitor.In conclusion, lncRNA TUG1 is positively correlated with advanced disease and poor prognosis, and it promotes cells proliferation and inhibits cells apoptosis in EOC cells.

Oxycodone versus dezocine for postoperative analgesia in patients with cervical cancer treated with radical surgery.

OBJECTIVE: The aim of this study was to evaluate oxycodone versus dezocine for postoperative analgesia in patients with cervical cancer treated with radical surgery. MATERIALS AND METHODS: Fifty-one cases of cervical cancer treated with radical surgery were included in the present study and divided into oxycodone group (n = 26) and dezocine group (n = 25). Patients in the oxycodone group were given with oxycodone 1 mg/kg plus tropisetron 0.1 mg/kg diluting to 100 ml by 0.9% saline for patient-controlled intravenous analgesia (PCIA) after surgery. Moreover, patients in the dezocine group were given with dezocine 0.6 mg/kg plus tropisetron 0.1 mg/kg diluting to 100 ml by 0.9% saline for PCIA after surgery. The visual analog scale (VAS) and Ramsay sedation score of the two groups were recorded in the time point of 4, 8, 12, 24, and 48 h after surgery. The adverse event-related drugs were recorded and compared between the two groups. RESULTS: The VAS score was significantly lower in oxycodone group compared to dezocine group in the time point of 4, 8, 12, 24, and 48 h (Pall < 0.05). The Ramsay score at time point of 4, 8, 12, 24 h, and 48 h were obviously higher in oxycodone group than those in dezocine group (P < 0.05) which indicated that the sedative effect in oxycodone group was superior to dezocine. For oxycodone group, there were six cases (23.08%) with nausea and one case (3.85) with vomiting in the treatment procedure. Moreover, for dezocine group, there were one case (4.00%) with nausea, two cases (8.00%) with vomiting, and two cases (8.00%) with dizzy in the treatment procedure. There was no statistical difference of adverse event risk between the two groups (P > 0.05). CONCLUSION: Oxycodone postoperative analgesia is superior to dezocine for patients with cervical cancer treated with radical surgery.